
Please try another search
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. Its lead product candidate is KRRO-110 which is in Phase 1/2 clinical trial for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson’s disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Rachel Meyers | 60 | 2023 | Independent Director |
Katharine Knobil | 60 | 2024 | Independent Director |
Noel Gerry McElvaney | - | 2024 | Member of Clinical Advisory Board |
Alice M. Turner | - | 2024 | Member of Clinical Advisory Board |
Monica Goldklang | - | 2024 | Member of Clinical Advisory Board |
Daniel Chambers | - | 2024 | Member of Clinical Advisory Board |
Pavel Strnad | - | 2024 | Member of Clinical Advisory Board |
Jeffrey H. Teckman | - | 2024 | Member of Clinical Advisory Board |
Ram Aiyar | 47 | 2020 | CEO, President & Director |
Ali Behbahani | 49 | 2023 | Independent Director |
Nessan Bermingham | 52 | 2023 | Co-Founder & Independent Chairman of the Board |
Jean-Francois Formela | 68 | 2023 | Co-Founder & Independent Director |
Timothy R. Pearson | 57 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review